What topics does this cannabis study cover?

This study covers research on: Addiction, Mental Health.

Where was this research published?

Published in Journal of dual diagnosis on June 11, 2026.

Addiction Mental Health

New antipsychotic shows promise for cannabis and addiction treatment

Dopamine Receptor Modulation in Co-Occurring Disorders: Potential of Cariprazine and D3 Receptor Activity.

Journal of dual diagnosis • June 11, 2026 • Moderately Relevant

🤖

AI Summary

This research paper examines how dopamine receptor-modulating medications, particularly antipsychotics, could help treat substance use disorders (SUDs) that often occur alongside serious mental illness. The study focuses on how dopamine receptors—especially the D3 receptor—control reward processing, craving, and relapse behaviors in people struggling with addiction. Traditional antipsychotics that heavily block dopamine receptors showed limited benefit or even worsened substance use outcomes, but newer antipsychotics with more selective profiles show promise. The paper emphasizes cariprazine, the only antipsychotic with high affinity for the D3 receptor, which has demonstrated potential benefits across preclinical studies and case reports, particularly for stimulant and cannabis use disorders.

Cariprazine's unique pharmacologic approach appears to offer dual benefits: reducing substance craving and relapse while simultaneously improving psychiatric symptoms in people with co-occurring mental illness and addiction. Research indicates that targeting the D3 receptor specifically may be more effective than older approaches that broadly suppressed dopamine signaling. Reported improvements include reductions in substance use frequency, decreased cravings, and lower relapse rates, with particularly encouraging results for cannabis and stimulant addiction. However, the current evidence base remains limited to small sample sizes, non-randomized studies, and inconsistent outcome measures, which means more rigorous research is needed before cariprazine can be widely recommended for addiction treatment.

The findings suggest an important shift in addiction pharmacology: rather than simply dampening dopamine signaling, selectively modulating dopamine receptors offers a more nuanced approach to treating both addiction and mental illness. This represents a promising direction for developing integrated treatments for the approximately 30-50% of people with serious mental illness who also struggle with substance use disorders. The authors call for large-scale randomized controlled trials to confirm cariprazine's effectiveness and determine how it fits into comprehensive addiction treatment programs.

📄 Original Abstract

Objective: Substance use disorders (SUDs) frequently co-occur with serious mental illness (SMI) and remain undertreated, in part due to limited pharmacologic options for many substances. Dopamine receptor-modulating agents (DRMAs), particularly antipsychotics with partial agonist activity, have been investigated for their potential to influence craving, reward processing, and relapse. This commentary reviews the evolving evidence for dopamine receptor modulation in SUDs, with particular emphasis on second-generation antipsychotics (SGAs) and the D3-preferring partial agonist cariprazine. Methods: A narrative review of preclinical, clinical, and observational literature was conducted, focusing on dopamine receptor antagonists and partial agonists studied in populations with SUDs, including individuals with co-occurring SMI. Particular attention was given to pharmacologic mechanisms involving D2 versus D3 receptor activity and to emerging evidence regarding cariprazine. Results: Early studies of first-generation antipsychotics, characterized by potent and sustained D2 receptor antagonism, generally demonstrated limited benefit or worsening of substance use outcomes. SGAs have shown more heterogeneous effects, likely reflecting variability in receptor-binding profiles and study methodologies. Increasing evidence highlights the role of the dopamine D3 receptor in substance-related motivation, reward, and cue reactivity. Cariprazine, the only currently approved antipsychotic with high affinity and preferential activity at the D3 receptor, has demonstrated potential benefits across preclinical models, case reports, and observational studies. Reported improvements include reductions in substance use, craving, and relapse-particularly for stimulant and cannabis use disorders-alongside improvements in psychiatric symptoms and functioning. However, most clinical evidence remains limited to small samples, non-randomized designs, and variable outcome measures. Conclusions: Dopamine receptor modulation, particularly targeting the D3 receptor, represents a promising but still emerging strategy for the treatment of SUDs, especially in individuals with co-occurring psychiatric disorders. Cariprazine's unique pharmacologic profile and broad clinical indications position it as a compelling candidate for further investigation. Rigorous randomized controlled trials using standardized substance use outcomes are needed to clarify its efficacy and role in integrated treatment models for dual diagnosis populations.

Paper Type

📄 Research

Publication

Journal: Journal of dual diagnosis
Published: June 11, 2026
PMID: 42274167
DOI: 10.1080/15504263.2026.2676699

Authors (3)

Sean T Lynch Division on Substance Use Disorders, Department of Psychiatry, Columbia University Irving Medical Center, New York State Psychiatric Institute, New York, New York, USA.
John J Mariani Division on Substance Use Disorders, Department of Psychiatry, Columbia University Irving Medical Center, New York State Psychiatric Institute, New York, New York, USA.
Frances R Levin Division on Substance Use Disorders, Department of Psychiatry, Columbia University Irving Medical Center, New York State Psychiatric Institute, New York, New York, USA.